ASHP Injectable Drug Information May 2023 Update

This update contains 10 new monographs, 40 revised monographs and 1 new MedWatch alert.

New monographs: Atezolizumab; Avelumab; Cemiplimab; Dostarlimab; Durvalumab; Ipilimumab; Nivolumab; Pembrolizumab; Terlipressin Acetate; tremelimumab.

Revised monographs: Acetylcysteine; Amoxicillin Sodium; Bamlanivimab; Bupivacaine Hydrochloride; Casirivimab-Imdevimab; Ceftriaxone Sodium; Coagulation Factor Xa (Recombinant), Inactivated-zhzo; Dexmedetomidine Hydrochloride; Dimenhydrinate; Diphenhydramine Hydrochloride; Etesevimab; Fat Emulsion, Intravenous; Fentanyl Citrate; Fluorouracil; Gentamicin Sulfate; Granisetron Hydrochloride; Heparin Sodium; Hyaluronidase; Hydrocortisone Sodium Succinate; Hydromorphone Hydrochloride; Ketamine Hydrochloride; Leucovorin Calcium; Methylprednisolone Acetate; Methylprednisolone Sodium Succinate; Midazolam Hydrochloride; Morphine Sulfate; Neostigmine Methylsulfate; Octreotide Acetate; Oliceridine Fumarate; Oxacillin Sodium; Penicillin G Potassium; Pentobarbital Sodium; Phenobarbital Sodium; Potassium Chloride; Promethazine Hydrochloride; Sodium Chloride; Sodium Lactate; Sotrovimab; Valproate Sodium; Vancomycin Hydrochloride.

New MedWatch alerts on the following monograph: Potassium Phosphates.